Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025CancersOpen Access

Dendritic Cells of Leukemic Origin (DCleu) Modulate the Expression of Inhibitory Checkpoint Molecules and Their Ligands on T Cells and Blasts in AML Relapse After Allogeneic Stem Cell Transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

XFXiaojia FengGVGiuliano Filippini VelázquezSBSophia Bohlscheid

Discussion

Loading...

Member takes

Overview

Flow cytometry analysis shows ICM expression alterations in T-cells after allo-HCT, suggesting immune modulation by DCleu.

Key Points

  • High frequencies of ICM-co-expressing T-cells and blasts were observed in patients with AML/MDS relapse.
  • Treatment with Kit M induced DCleu that downregulated ICM-expressing T-cells while enhancing immune activation.
  • Post-MLC, there was no correlation between ICM modulation and patients' clinical response to relapse treatment.
  • The study indicates that Kit M may help in overcoming impaired antileukemic reactions in relapsed AML patients.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/68d4263f713b0b5dfea6ca44https://doi.org/10.3390/cancers17182948
View Full Paper
Ask AI
Bookmark
Share